Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines-9

�mol/L gefitinib plus 10 nM EGF (Gb + E). ANOVA One-way analysis of variance and Tukey's Multiple Comparison Test. Caco-2. NT vs: **E, ***Cx5, *Cx10, ***Gb, ***Cx5 + E, *Cx10 + E, **Gb + E. *p < 0.05, **p < 0.01, ***p < 0.001. Each point represents a mean of quadruplicate values for each sample ± SD.<p><b>Copyright information:</b></p><p>Taken from "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines"</p><p>http://www.biomedcentral.com/1471-2407/8/227</p><p>BMC Cancer 2008;8():227-227.</p><p>Published online 8 Aug 2008</p><p>PMCID:PMC2528013.</p><p></p

Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines-1

<p><b>Copyright information:</b></p><p>Taken from "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines"</p><p>http://www.biomedcentral.com/1471-2407/8/227</p><p>BMC Cancer 2008;8():227-227.</p><p>Published online 8 Aug 2008</p><p>PMCID:PMC2528013.</p><p></p

Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines-5

En samples.<p><b>Copyright information:</b></p><p>Taken from "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines"</p><p>http://www.biomedcentral.com/1471-2407/8/227</p><p>BMC Cancer 2008;8():227-227.</p><p>Published online 8 Aug 2008</p><p>PMCID:PMC2528013.</p><p></p

Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines-3

Y as untreated cells. c. 10 nmol/L cetuximab treated cells. Filopodi are evident. Insert: microvilli reduction is evident. d. 10 nmol/L cetuximab plus 10 nM EGF treated cells. Filipodi and some vesicles are evident. Insert: microvilli reduction is evident. e. 1 μmol/L gefitinib treated cells. Some vesicles are evident. Insert: microvilli reduction is evident. f. 1 μmol/L gefitinib plus 10 nM EGF treated cells. Lamellipodi, some vesicles and weak contacts with nearby cells are evident. Insert: microvilli reduction is evident.<p><b>Copyright information:</b></p><p>Taken from "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines"</p><p>http://www.biomedcentral.com/1471-2407/8/227</p><p>BMC Cancer 2008;8():227-227.</p><p>Published online 8 Aug 2008</p><p>PMCID:PMC2528013.</p><p></p

All heat maps were obtained by using an unsupervised hierarchical clustering method with a correlation distance between all the samples and between the selected genes

Heat map of genes selected from 10 nM EGF treated samples.<p><b>Copyright information:</b></p><p>Taken from "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines"</p><p>http://www.biomedcentral.com/1471-2407/8/227</p><p>BMC Cancer 2008;8():227-227.</p><p>Published online 8 Aug 2008</p><p>PMCID:PMC2528013.</p><p></p

Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines-4

Li are present. b. EGF treated cells. A lot of vesicles are evident. Insert: a small number of microvilli are present. c. 10 nmol/L cetuximab treated cells. The microvilli diminish in number and lose their erect position. Insert: microvilli make contacts forming a star morphology. d. 10 nmol/L cetuximab plus 10 nM EGF treated cells. Same morphology as 10 nmol/L cetuximab treated cells. e. 1 μmol/L gefitinib treated cells. The microvilli diminish in number and lose their erect position. Insert: microvilli make contacts forming a star morphology. f. 1 μmol/L gefitinib plus 10 nM EGF treated cells. Same morphology as 1 μmol/L gefitinib treated cells.<p><b>Copyright information:</b></p><p>Taken from "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines"</p><p>http://www.biomedcentral.com/1471-2407/8/227</p><p>BMC Cancer 2008;8():227-227.</p><p>Published online 8 Aug 2008</p><p>PMCID:PMC2528013.</p><p></p

Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines-0

�mol/L gefitinib plus 10 nM EGF (Gb + E). ANOVA One-way analysis of variance and Tukey's Multiple Comparison Test. Caco-2. NT vs: **E, ***Cx5, *Cx10, ***Gb, ***Cx5 + E, *Cx10 + E, **Gb + E. *p < 0.05, **p < 0.01, ***p < 0.001. Each point represents a mean of quadruplicate values for each sample ± SD.<p><b>Copyright information:</b></p><p>Taken from "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines"</p><p>http://www.biomedcentral.com/1471-2407/8/227</p><p>BMC Cancer 2008;8():227-227.</p><p>Published online 8 Aug 2008</p><p>PMCID:PMC2528013.</p><p></p

Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines-2

treated). HT-29. Continuous moderate to strong membrane staining is present in untreated and cetuximab or gefitinib treated cells. Strong granular cytoplasmic immunostaining was present for all treatments plus EGF, without any observable membrane staining. Caco-2. Continuous weak to moderate membrane brown staining is present in untreated as well as in cetuximab 5 nmol/L and gefitinib 1 μmol/L treated cells. Weak membrane immunostaining was present in cetuximab 10 nmol/L treated cells. The cytoplasmic immunostaining pattern was granular in EGF 10 nM, diffuse in gefitinib 1 μmol/L plus EGF 10 nM and a mixture of the two (granular and diffuse) in cetuximab 5 and 10 nmol/L plus EGF 10 nM treated cells.<p><b>Copyright information:</b></p><p>Taken from "Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines"</p><p>http://www.biomedcentral.com/1471-2407/8/227</p><p>BMC Cancer 2008;8():227-227.</p><p>Published online 8 Aug 2008</p><p>PMCID:PMC2528013.</p><p></p